Masimo Corporation
HealthcareNASDAQ:MASI · NASDAQ Global Select
+$0.00 today
Vol 0.00M · Avg 1.08M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.6B of revenue converted into $76.3M of net income for the selected period. Gross margin is 61.8% and net margin is 4.4%, showing how much revenue survives after costs and taxes. EPS is $1.46, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B -27.1% | $2.1B +2.3% | $2.0B +0.6% | $2.0B +64.3% | $1.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $581.7M -46.6% | $1.1B +4.3% | $1.0B +6.9% | $977.0M +126.8% | $430.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $945.2M -5.9% | $1.0B +0.1% | $1.0B -5.2% | $1.1B +31.0% | $808.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 61.9% +13.9pp | 48.0% -1.0pp | 49.0% -3.0pp | 52.0% -13.2pp | 65.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $126.4M -43.3% | $222.8M +27.2% | $175.2M -8.5% | $191.4M +39.5% | $137.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $506.0M -32.0% | $743.8M +12.0% | $664.0M +1.0% | $657.4M +66.3% | $395.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $632.4M -50.2% | $1.3B +46.6% | $867.0M +2.1% | $848.8M +59.4% | $532.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $38.8M -62.3% | $103.0M +4.8% | $98.3M -27.8% | $136.1M +282.3% | $35.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | $344.6M +317.1% | -$158.7M -167.0% | $236.7M -33.4% | $355.2M +14.5% | $310.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 22.6% +30.1pp | -7.6% -19.1pp | 11.6% -5.9pp | 17.4% -7.6pp | 25.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $312.8M +217.3% | -$266.7M -295.4% | $136.5M -35.0% | $210.0M -23.9% | $275.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 20.5% +33.2pp | -12.7% -19.4pp | 6.7% -3.7pp | 10.3% -11.9pp | 22.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.4M -29.2% | $4.8M +60.0% | $3.0M +66.7% | $1.8M +100.0% | $900.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $33.2M -23.9% | $43.6M -13.3% | $50.3M +95.7% | $25.7M +8466.7% | $300.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$40.2M -4.1% | -$38.6M +20.2% | -$48.4M -191.6% | -$16.6M -1085.7% | -$1.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $272.6M +189.3% | -$305.3M -446.5% | $88.1M -54.4% | $193.4M -29.5% | $274.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 17.9% +32.4pp | -14.6% -18.9pp | 4.3% -5.2pp | 9.5% -12.6pp | 22.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $64.9M +16325.0% | -$400.0K -106.1% | $6.6M -86.8% | $49.9M +11.4% | $44.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$151.5M +50.3% | -$304.9M -474.1% | $81.5M -43.2% | $143.5M -37.5% | $229.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -9.9% +4.6pp | -14.6% -18.5pp | 4.0% -3.1pp | 7.0% -11.5pp | 18.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 +50.5% | -$6 -471.4% | $2 -42.5% | $3 -35.6% | $4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 +51.0% | -$6 -478.8% | $2 -41.9% | $3 -34.7% | $4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $53.6M +0.6% | $53.3M +0.9% | $52.8M -1.5% | $53.6M -2.8% | $55.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $54.2M +1.7% | $53.3M -1.5% | $54.1M -2.0% | $55.2M -4.3% | $57.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Baxter International Inc.
NYSE:BAX
$10.74B
Molina Healthcare, Inc.
NYSE:MOH
$10.43B
Henry Schein, Inc.
NASDAQ:HSIC
$9.31B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.72B
AptarGroup, Inc.
NYSE:ATR
$7.54B
Repligen Corporation
NASDAQ:RGEN
$7.49B
Avantor, Inc.
NYSE:AVTR
$6.54B
Abivax S.A.
NASDAQ:ABVX
$6.35B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.04B
Stevanato Group S.p.A.
NYSE:STVN
$4.67B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MASI generate?
Masimo Corporation (MASI) reported $1.53B of revenue in fiscal 2025.
Is MASI profitable?
Masimo Corporation (MASI) reported -$151,500,000.00 of net income, with a net margin of -9.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.